This bill aims to support the development of medications for rare diseases by improving incentives for drug companies, especially in light of challenges from the COVID-19 pandemic.
Leo's Law This bill extends by 180 days the relevant periods of market exclusivity for drugs for rare diseases or conditions (i. e., orphan drugs) for which applications were submitted during the COVID-19 emergency period.